Antistaphylococcal activities of CG400549, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 3, 2007, Pages 568-574

  Park, Hee Soo ^a,b   Yoon, Yu Min ^a   Jung, Sung Ji ^a   Kim, Cheol Min ^b   Kim, Jeong Mi ^b   Kwak, Jin Hwan ^a  

^a Handong University   (South Korea)

^b CrystalGenomics Inc   (South Korea)

Author keywords

Antibacterial activity; Mode of action; Resistance mechanism

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CG 400549; CIPROFLOXACIN; DALFOPRISTIN PLUS QUINUPRISTIN; ENOYL ACYL CARRIER PROTEIN REDUCTASE (FABI); ENOYL ACYL CARRIER PROTEIN REDUCTASE (FABI) INHIBITOR; ERYTHROMYCIN; FATTY ACID; GEMIFLOXACIN; LINEZOLID; MOXIFLOXACIN; OXACILLIN; OXIDOREDUCTASE; SPARFLOXACIN; TRICLOSAN; UNCLASSIFIED DRUG; VANCOMYCIN;

AGAR GEL DIFFUSION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIOSTASIS; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; FATTY ACID SYNTHESIS; GENE OVEREXPRESSION; IN VITRO STUDY; IN VIVO STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; BENZAMIDINES; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; GUANIDINES; HUMANS; MICROBIAL SENSITIVITY TESTS; NEUTRAL RED; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAZOLIUM SALTS; THIAZOLES;

EID: 34548118787     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm236     Document Type: Article

References (32)

1. Bell JM, Turnidge JD. High prevalence of oxacillin-resistant Staphylococcus aureus isolates from hospitalized patients in Asia-Pacific and South Africa: Results from SENTRY Antimicrobial Surveillance Program, 1998-1999. Antimicrob Agents Chemother 2002; 46: 879-81.
2. Levy SB, Marshall B. Antibacterial resistance worldwide: Causes, challenges and responses. Nat Med 2004; 10: S122-129.
3. Zetola N, Francis JS, Nuernberger EL et al. Community-acquired methicillin-resistant Staphylococcus aureus: An emerging threat. Lancet Infect Dis 2005; 5: 275-86.
4. Hiramatsu K, Hanaki H, Ino T et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40: 135-6.
5. Cosgrove SE, Carroll KC, Perl TM. Staphylococcus aureus with reduced susceptibility to vancomycin, Clin Infect Dis 2004; 39 539-45.
6. Linda MW, Clewell DB, Gill SR et al. Genetic analysis of a high-level vancomycin-resistant isolate of Staphylcoccus aureus. Science 2003; 302: 1569-71.
7. Song JH, Hiramatsu K, Suh JY et al. Emergence in Asian countries of Staphylococcus aureus with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 2004; 48: 4926-8.
8. Bax R, Mullan N, Verhoef J. The millennium bugs: The need for and development of new antibacterials. Int J Antimicrob Agents 2000; 16: 51-9.
9. Lynn M, Jonathan G, Todd AB. Genetic strategies for antibacterial drug discovery, Nature 2003; 4: 442-56.
10. Molly BS. Seeing is believing: The impact of structural genomics on antimicrobial drug discovery. Nat Rev Microbiol 2004; 2: 739-46.
11. Heath RJ, White SW, Rock CO. Lipid biosynthesis as a target for antibacterial agents. Prog Lipid Res 2001; 40: 467-97.
12. Heath RJ, Rock CO. Enoyl-acyl carrier protein reductase (fabl) plays a determinant role in completing cycles of fatty acid elongation in Escherichia coli. J Biol Chem 1995; 270: 26538-42.
13. Heath RJ, Rock CO. Regulation of fatty acid elongation and initiation by acyl-acyl carrier protein in Escherichia coli. J Biol Chem 1996; 271: 1833-6.
14. McMurry LM, Oethinger M, Levy SB. Triclosan targets lipid synthesis. Nature 1998; 394: 531-2.
15. Slater-Radosti C, Van-Aller G, Greenwood R et al. Biochemical and genetic characterization of the action of triclosan on Staphylococcus aureus. J Antimicrob Chemother 2001; 48: 1-6.
16. Oh JI, Paek KS, Ahn MJ et al. In vitro and in vivo evaluations of LB20304 a new fluoronahthyridone. Antimicrob Agents Chemother 1996; 40:1564-8.
17. Park HS, Kim HJ, Seol MJ et al. In vitro and in vivo antibacterial activities of DW-224a, a new fluoronaphthyridone. Antimicrob Agents Chemother 2006; 50: 2261-4.
18. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Fifteenth Informational Supplement M100-S15. CLSI, Wayne, PA, USA, 2005.
19. Bliss CI. Statistics in Bioassay. New York: Academic Press, Inc., 1985.
20. National Committee for Clinical Laboratory Standards. Methods for Determining Bactericidal Activity of Antimicrobial Agents: Approved Guideline M26-A. NCCLS, Wayne, PA, USA, 1999.
21. Kwak JH, Weisblum B. Regulation of plasmid pE194 replication: Control of cop-repF operon transcription by Cop and of repF translation by countertranscript RNA. J Bacteriol 1994; 176: 5044-51.
22. Kraemer GR, Iandolo JJ. High frequency transformation of Staphylococcus aureus by electroporation. Curr Microb 1990; 21: 373-6.
23. Spellberg B, Powers JH, Brass EP et al. Trends in antimicrobial drug development: Implications for the future. Clin Infect Dis 2004; 38: 1279-86.
24. Luh KT, Hsueh PR, Teng LJ et al. Quinupristin-dalfopristin resistance among Gram-positive bacteria in Taiwan. Antimicrob Agents Chemother 2000; 44: 3374-80.
25. Losee LL, Xian J, Ali S et al. Identification and characterization of inhibitors of bacterial enoyl-acyl carrier protein reductase. Antimicrob Agents Chemother 2004; 48: 1541-7.
26. Moir DT. Identification of inhibitors of bacterial enoyl-acyl carrier protein reductase. Curr Drug Targets Infect Disord 2005; 5: 297-305.
27. Payne DJ, Miller WH, Berry W et al. Discovery of a novel and potent class of Fabl-directed antibacterial agents. Antimicrob Agents Chemother 2002; 46: 3118-24.
28. Seefeld MA, Miller WH, Newlander KA et al. Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases Fabl and FabK. J Med Chem 2003; 46: 1627-35.
29. Marrakchi H, Dewolf WE, Quinn C et al. Characterization of Straplococcus pneumoniae enoyl-(acyl-carrier protein) reductase (FabK). Biochem J 2003; 370: 1055-62.
30. Heath RJ, Yu UT, Shapiro MA et al. Inhibition of the Staphylocoocus aureus NADPH-dependent enoyl-acyl carrier protein reductase by triclosan and hexachlorophene. J Biol Chem 2000; 275: 4654-9.
31. Frank F, Yan K, Wallis NG et al. Defining and combating the mechanisms of triclosan resistance in clinical isolates of Staphhylococcus aureus. Antimicrob Agents Chemother 2002; 46: 3343-7.
32. Brenwald NP, Fraise AP. Triclosan resistance in methicillin-resistant Staphylococcus aureus. J Hosp Infect 2003; 55: 141-4.